 A significant and far reaching decision by the FDA under her tenure, was the ban on supplements and natural products that contain lovastatin, effectively handing exclusivity of cholesterol lowering compounds to pharmaceutical companies.AstraZeneca benefited directly from this decision this removed a cheap, natural product, from competing with their own statin rosuvastatin.She was named senior vice president and provost for health affairs at the University of Cincinnati in 2003.